[
  {
    "page": 2,
    "source": "table",
    "content": "Sustainable Procurement\nQuality Manufacturing and Patient Safety"
  },
  {
    "page": 2,
    "source": "table",
    "content": "About This Report\n2022 Reporting"
  },
  {
    "page": 5,
    "source": "table",
    "content": "Performance\t\t\tIndustry Ranking\t\t\n\t\t2020\t2021\t2022\t2020\t2021\t2022\n\t\t36\t41\t54\tTop 30%\tTop 17%\tTop 7%\n\t\t33.3 (High risk)\t31.1 (High risk)\t29.8(Medium risk)\tTop 10%\tTop 12%\tTop 18%\n\t\t3.3 (B)\t3.4 (B)\t3.7 (BB)\tNA\tNA\tNA\n\t\t37\tNA\t42\tNA\tNA\tNA\n\t\tC\tC+\tC+\tTop 40%\tTop 10%\tTop 10%\n\t\t56\t63\t67\tTop 23%\tTop 12%\tTop 9%\nCLIMATE\nWATER\tCLIMATE\tA-\tB\tA-\tNA\tNA\tNA\n\tWATER\tC\tB\tB\tNA\tNA\tNA"
  },
  {
    "page": 7,
    "source": "table",
    "content": "Oncology\t\nCentral Nervous\nSystem\t\nRespiratory"
  },
  {
    "page": 10,
    "source": "table",
    "content": "Topic\tSubtopic\tLong-term Quantitative Targets\tProgress\tStatus\nClimate Action\nand Resilience\tGreenhouse Gas\n(GHG) Emissions\tReduce absolute scope 1 and 2 GHG emissions by 25% by 2025 and by 46% by\n2030 (vs. 2019)2\tReduced by 24%\t\n\t\tReduce absolute scope 3 GHG emissions by 25% by 2030 (vs. 2020)\tReduced by 12%\t\n\tEnergy\tIncrease energy efficiency by revenue (kWh/USD revenue) by 10%\nby 2030 (vs. 2020)\tAchieved at 10%\t\n\t\tIncrease total proportion of electricity purchased or generated from renewable\nsources to 50% by 2030\tIncreased by 8% (vs. 2021) to 41%\t\nResponsible Use\nof Natural Resources\tWater\tReduce total water withdrawal by 10% in areas projected to be in water stress\nby 2030 (vs. 2020)\tAchieved at 17% reduction\t\n\tPackaging Materials\tIncrease the proportion of recycled and responsibly sourced materials\nby 10% by 2030 (vs. 2025)\tBaseline to be defined\t\nEffluents\nand Waste\tAntimicrobial\nResistance\tMeet AMR (antimicrobial resistance) Industry Alliance commitment to minimize\nantimicrobial discharges by assessing 100% of Teva sites that are handling drug\nproducts by 2030\tAchieved, assessed 33 sites\t\n\t\tMeet AMR Industry Alliance commitment to minimize antimicrobial discharges\nby assessing 50% of antimicrobial drug product and drug substance supply\nby 2030\tImplementation of strategy to start\nin 2023\t\nAccess to Health\nand Medicines\tAccess Strategy\tContinue to be a leader and trusted partner for healthcare organizations in\nemergencies, disasters and pandemics\tUkraine emergency donation\nand new agreement for Strategic\nEmergency Stockpile\t\n\t\tQuantify savings of quality generics to health systems\t$44B in savings across 21 countries\t\n\tAccess Programs\tLaunch eight access programs by 2025 that address vulnerable populations\nand those in the last mile in low- and middle-income countries (LMICs)\t5 programs launched\n(62% of the target)\t\n\tSubmissions/\nApprovals\tIncrease the cumulative number of new regulatory submissions in LMICs on the\nWorld Health Organization’s (WHO) Essential Medicine List (EML) across six key\ntherapeutic areas (TAs) by 150% from 2022 to 2025 (vs. 2017-2020)2\t21 submissions (28% of the target)"
  },
  {
    "page": 11,
    "source": "table",
    "content": "Topic\tSubtopic\tLong-term Quantitative Targets\tProgress\tStatus\nAccess to Health\nand Medicines\tAccess Program\nProduct Volume\tIncrease access to medicine program product volume by 150% in 2025 (vs. 2020)\nthrough four access to medicine programs, including donations and social\nbusiness in LMICs on the WHO EML across six key TAs2\t361,711 single unit doses\t\n\t\tEnsure consideration of access to medicines strategy for new product launches\n(by 2023 and beyond)\tBenchmarking initiated\t\nBusiness Ethics,\nAnti-bribery and\nAnti-corruption4\tTraining\tTrain or retrain 100%3 of active employees on applicable Teva compliance\npolicies by 2023\t99.57% of target audience trained\t\n\t\tTrain or retrain 100%3 of active sales employees on compliance policies related\nto marketing practices by 2023\t99.57% of target audience trained\t\n\tEvaluation Processes\tMaintain annual 100% evaluation of submitted high-risk third-party business\npartners through Teva’s Third-Party Due Diligence tool\t100% evaluation\t\n\tCulture of Compliance\tTrain new employees and retrain 100%3 of active employees on how to report\nconcerns through the Teva Integrity Hotline by 2023\t99.57% of target audience trained\t\n\t\tStrengthen Teva’s culture of compliance, keeping our Gartner global index score at\nparity or greater than external benchmark by 2022\tResults at parity with benchmarks\t\nData Privacy\nand Security\tTraining\tTrain 100%3 of employees who process personal data on Teva’s privacy\npolicies by 2022\t99.41% of active employees trained\t\nResponsible\nSupply Chain\tAssessment\tAssess 100% of critical suppliers on ESG performance by 2025\t56% of suppliers assessed\t\n\t\tAchieve bronze or higher score for more than 75% of critical suppliers\nin EcoVadis by 2025\t46% have bronze or higher score\t\n\t\tAchieve silver or higher score for more than 50% of critical suppliers\nin EcoVadis by 2025\t31% have silver or higher score"
  },
  {
    "page": 16,
    "source": "table",
    "content": "Progress\t\nClimate\nAction and\nResilience\tReduce absolute scope 1 and 2 greenhouse gas (GHG) emissions by 25% by 2025 and\nby 46% by 2030 (vs. 2019)2\tReduced by 24%\t\n\tReduce absolute scope 3 GHG emissions by 25% by 2030 (vs. 2020)\tReduced by 12%\t\n\tIncrease energy efficiency (kWh/USD revenue) by 10% by 2030 (vs. 2020)\tAchieved at 10%\t\n\tIncrease total proportion of electricity purchased or generated from renewable sources\nto 50% by 2030\tIncreased by 8% (vs. 2021)\nto 41%\t\nResponsible\nUse of\nNatural\nResources\tReduce total water withdrawal by 10% in areas projected to be in water stress\nby 2030 (vs. 2020)\tAchieved at 17% reduction\t\n\tIncrease the proportion of recycled and responsibly sourced materials by 10%\nby 2030 (vs. 2025)\tBaseline to be defined\t\n\tReduce the overall mass of secondary and tertiary packaging materials per unit dose\nby 2030\tStrategy in development\t\n\tAssess the environmental life cycle impact of key products by 2030\t2 LCAs performed to date\t\n\tMeet AMR Industry Alliance commitment to minimize antimicrobial discharges by\nassessing 100% of Teva sites that are handling drug products by 2030\tAchieved, assessed 33 sites\t\n\tMeet AMR Industry Alliance commitment to minimize antimicrobial discharges by\nassessing 50% of antimicrobial drug product and drug substance supply by 2030\tImplementation of strategy to start\nin 2023\t\n\tAssess and mitigate the environmental impact of pharmaceutical ingredients used in\noperations\t6 sites handling priority APIs\nassessed in 2022\t\n\tContinue to minimize waste generated from operations and the environmental impact\nof its disposal by 2030\t32% reduction in total waste\ngenerated (vs. 2020) and 3%\nincrease in proportion of waste\nrecovered (vs. 2020)"
  },
  {
    "page": 21,
    "source": "table",
    "content": "2\t\t\n4"
  },
  {
    "page": 21,
    "source": "table",
    "content": "9\t\t\n5"
  },
  {
    "page": 21,
    "source": "table",
    "content": "1\t\t\n\t\t\n3"
  },
  {
    "page": 24,
    "source": "table",
    "content": "Progress\t\nContinue to be a leader and trusted partner for\nhealthcare organizations in emergencies,\ndisasters and pandemics\tUkraine emergency donation\nand new agreement for\nStrategic Emergency Stockpile\t\nQuantify savings of quality generics\nto health systems\t$44B in savings across\n21 countries\t\nLaunch eight access programs by 2025\nthat address vulnerable populations and\nthose in the last mile in LMICs\t5 programs launched\n(62% of the target)\t\nIncrease the cumulative number of new\nregulatory submissions in LMICs on the WHOs\nEML across six key TAs by 150% from 2022 to\n2025 (vs. 2017-2020)2\t21 submissions\n(28% of the target)\t\nIncrease access to medicine program product\nvolume by 150% in 2025 (vs. 2020) through\nfour access to medicine programs, including\ndonations and social business in LMICs on the\nWHOs Essential Medicines List (EML) across six\nkey therapeutic areas (TAs)2\t361,711 single unit doses\t\n\tBenchmarking initiated"
  },
  {
    "page": 29,
    "source": "table",
    "content": "2019\t2020\t2021\t2022\nChange (%) in average list\nprice across US innovative\nmedicine portfolio compared\nto previous year\t3.78\t2.12\t3.24\t3.74\nChange (%) in average net\nprice across US innovative\nmedicine portfolio compared\nto previous year\tNA\tNA\t-0.32"
  },
  {
    "page": 30,
    "source": "table",
    "content": "5%\nInfec\n23%\nMigr\n31N%eur\n5%Onco\nRese\n24%\nResp\n10%\nWom\n2%\tInfectious diseases\ntious diseases\nMigraine/pain\naine/pain\nNoleougryo/lopgsyyc/hpisaytcryhiatry\nOlongcyology\narch innovations\nResearch innovations\niratory\nRespiratory\nen's health\nWomen’s health"
  },
  {
    "page": 35,
    "source": "table",
    "content": "utiv\tes\t/\tM\tidd\tle\t\t\t\tJu\tnio\tr\t\tT\t\tota\tl\t\t\t\tProfe\t\tssio\tna\t\tls\t\tEntr\ty L\teve\t\tl\t\tT\tota\tl"
  },
  {
    "page": 39,
    "source": "table",
    "content": "Employee Turnover Rates\t\n\t8% 8% 8%\n5%\t\n\t2021 2022\nVoluntary Turnover Involuntary Turnover"
  },
  {
    "page": 41,
    "source": "table",
    "content": "Progress\t\nTotal Recordable Incident Rate (OSHA TRIR) of 0.23 or less\nby 20226\t0.24\t\nProcess Safety Event Rate (PSER) of 0.028 or less by 2022\t0.015\t\nNew Goals\t\t\nTotal Recordable Incident Rate (OSHA TRIR) of 0.25 or less by 2023"
  },
  {
    "page": 47,
    "source": "table",
    "content": "88\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n58\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n29\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t18 15\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t2\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\tTeva’sE Euurrooppee Regio\t\t\t\t\tn Tev"
  },
  {
    "page": 51,
    "source": "table",
    "content": "Progress\t\nTraining\tTrain or retrain 100%7 of active employees on applicable\nTeva compliance policies by 2023\t99.57% of target\naudience trained\t\n\tTrain or retrain 100%7 of active sales employees on\ncompliance policies related to marketing practices by 2023\t99.57% of target\naudience trained\t\nEvaluation\nProcesses\tMaintain annual 100% evaluation of submitted high-risk\nthird-party business partners through Teva's Third-Party\nDue Diligence tool\t100% evaluation\t\nCulture of\nCompliance\tTrain new employees and retrain 100%7 of active employees\non how to report concerns through the Teva Integrity\nHotline by 2023\t99.57% of target\naudience trained\t\n\tStrengthen Teva’s culture of compliance, keeping our\nGartner global index score at parity or greater than external\nbenchmark by 2022\tResults at parity\nwith benchmarks\t\nNew Goals\t\t\t\nTraining\tTrain 100%7 of targeted active employees in annual GC&E training campaigns\t\t\n\tRecertify 100%7 of active employees on the Code of Conduct in 2024\t\t\nCulture of\nCompliance\tIntroduce new compliance and ethics questions into the 2023 Organizational Health Survey\n(OHS) and establish a 2023 baseline to measure Teva’s future performance on the culture of\ncompliance and ethics"
  },
  {
    "page": 55,
    "source": "table",
    "content": "Progress\t\nAssess 100% of critical suppliers on ESG\nperformance by 2025\t56% of suppliers\nassessed\t\nAchieve bronze or higher score for more than 75% of\ncritical suppliers in EcoVadis by 2025\t46% have bronze\nor higher score\t\n\t31% have silver or\nhigher score"
  },
  {
    "page": 57,
    "source": "table",
    "content": "Supplier Diversity in the US\n900\n800 777\n700\n600\n499\n500\n400\n300\n200\n166\n131\n100 90\n65\n39\n19\n0\nSmall businesses Women-owned Small Veteran-owned\nsmall businesses disadvantaged small businesses\nbusinesses\n2021 2022"
  },
  {
    "page": 57,
    "source": "table",
    "content": "65"
  },
  {
    "page": 57,
    "source": "table",
    "content": "0"
  },
  {
    "page": 61,
    "source": "table",
    "content": "Progress\n99.41% of active\nemployees\ntrained"
  },
  {
    "page": 65,
    "source": "table",
    "content": "Employee information and diversity:\n• GRI 2-7 Employees • GRI 401-1 New employee hires and employee turnover\n• GRI 2-8 Workers who are not employees • GRI 405-1 Diversity of governance bodies and employees\n• GRI 2-30 Collective bargaining agreements\nWater and effluents:\n• GRI 303-1 Interactions with water as a shared resource • GRI 303-4 Water discharge\n• GRI 303-2 Management of water discharge-related impacts • GRI 303-5 Water consumption\n• GRI 303-3 Water withdrawal"
  }
]